Clinical trials: Hair Problems, open to volunteers
Hair Thinning
Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth using an active gummy treatment in women with self-perceived thinning hair. The main aims of this trial are: 1.
- Trial name
- NCT07224555
- Testing
- Xtressé Hair Growth Gummies
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Alopecia Areata, Alopecia Totalis
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT06747611
- Testing
- Vancomycin, Neomycin and MTT capsules
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Psoriasis, Atopic Dermatitis
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12…
- Conditions
- Psoriasis, Atopic Dermatitis, Vitiligo, Alopecia Areata
- Trial name
- LANDSCAPE (NCT07336641)
- Testing
- Conventional Systemic Therapies, Biologic Therapies
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- Fondazione ISIDE
Androgenetic Alopecia
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.
- Trial name
- NCT07080931
- Testing
- 5% minoxidil foam
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Androgenetic Alopecia
Evaluation of Exosomes Injection in Treatment of Male Androgenetic Alopecia: Clinical and Immunohistochemical Study
Intradermal injection of exosomes in treatment of male androgenetic alopecia, clinically and using a immunohistochemical marker
- Trial name
- NCT07112586
- Testing
- Plasma derived exosomes
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Ain Shams University
Alopecia Areata
Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata
Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss of the scalp or any hair-bearing surface. Alopecia areata affects approximately 2% of the general population.
- Trial name
- NCT06399783
- Testing
- Simvastatin, Mometasone Furoate, Fractional CO2 laser
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Assiut University
PCOS (Polycystic Ovary Syndrome), Obese Adolescents
Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)
This pilot randomized controlled study will plan to enroll 36 adolescent females with Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) to evaluate the effectiveness and feasibility of a tailored…
- Conditions
- PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents
- Trial name
- Beef+ (NCT07780188)
- Testing
- Beef+
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Texas A&M University
Androgenic Alopecia
Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia
Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical…
- Trial name
- NCT07502976
- Testing
- Topical 2-Deoxy-D-ribose Hydrogel, Topical Minoxidil 5% Solution
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Kasr El Aini Hospital
Vitiligo Vulgaris, Psoriasis
PALLAS Laser for Skin Diseases
The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis).
- Conditions
- Vitiligo Vulgaris, Psoriasis, Alopecia Areata, Atopic Dermatitis
- Trial name
- PALLAS-UV (NCT07250997)
- Testing
- UVB laser treatment
- Where
- Hungary
- Volunteers
- 50 people
- Sponsor
- Szeged University
Menkes Disease
NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease
This clinical trial will evaluate the safety, tolerability, dosing, and efficacy of Northera (Droxidopa) in children with Menkes disease aged 7 to 17 years who survived the major neurodegenerative and neurocognitive effects of…
- Trial name
- NCT07398508
- Testing
- Droxidopa Oral Product
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stephen G. Kaler
Alopecia Areata
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
- Trial name
- NCT06104839
- Testing
- NXC736
- Where
- 2 sites in South Korea
- Volunteers
- 73 people
- Sponsor
- NEXTGEN Bioscience
PCO - Polycystic Ovaries, Obesity and Obesity-related Medical Conditions
The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Polycystic Ovary Syndrome
Abstract Background: This trial aims to investigate the effect of 12 weeks of 10 mg/day astaxanthin (ASX) administration compared with the control group on insulin sensitivity, lipid profile, circulating MDA levels, severity of…
- Trial name
- NCT06642363
- Testing
- Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the "Zyest Technology Tarawat Zendig" institute in Iran. The dosage of ASX is determined based on the s
- Where
- Iran
- Volunteers
- 44 people
- Sponsor
- Isfahan University of Medical Sciences
Alopecia Areata
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
- Trial name
- NCT07205159
- Testing
- FB102
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 32 people
- Sponsor
- Forte Biosciences, Inc.
Alopecia Areata
Dupilumab in the Treatment of Pediatric Alopecia Areata
This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study will take place at four sites. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at…
- Trial name
- PEDAL (NCT05866562)
- Testing
- Dupilumab
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia.
The goal of this study is to learn if mesenchymal stem cell therapy (treatment group) can effectively treat adrogenic alopecia or male-pattern baldness, when compared to normal saline (given to placebo group).
- Trial name
- NCT06764329
- Testing
- Mesenchymal Stem Cells, 0.9 % saline
- Where
- 2 sites in Pakistan
- Volunteers
- 70 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Androgenic Alopecia, Healthy Adult Male
Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia
The goal of this clinical trial is to evaluate the efficacy and safety of two different formulations of a food supplement on hair health in healthy Caucasian male subjects aged 35 to 65 years with mild to moderate androgenetic…
- Trial name
- NCT07806474
- Testing
- formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast, formulation of grape seed extract, bamboo shoot extract and selenium-enriched yeast
- Where
- 6 sites in Italy
- Volunteers
- 99 people
- Sponsor
- Activ'inside
Hair Loss/Baldness, Wrinkle Appearance
Autologous Adipose Cells Therapy
Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes.
- Conditions
- Hair Loss/Baldness, Wrinkle Appearance, Volume, Fine Lines
- Trial name
- NCT06869252
- Testing
- Autologous Adipose Cells Therapy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- CERM INC.
Severe Alopecia Areata
Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of severe alopecia areata.
- Trial name
- NCT06562894
- Testing
- SYHX1901
- Volunteers
- 156 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Alopecia Areata
A Study of LAD603 in Adults With Alopecia Areata
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA).
- Trial name
- NCT07311564
- Testing
- LAD603
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Almirall, S.A.
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.